AbbVie Inc. (ABBV) last closed at $265.08, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for ABBV, covered for search and blurred for visitors.
Performance
1D-1.48%
5D+0.47%
1M+7.39%
3M+10.85%
6M+42.04%
1Y+22.73%
5Y+162.42%
Financials
Over the latest four reported periods ending June 30, 2026, AbbVie Inc. reported revenue of $64.39 billion.
The prior window totaled $58.33 billion, so the latest window is higher than that stretch.
Operating cash flow in the latest window was $19.51 billion.
Free cash flow in the latest window was $18.21 billion.
These amounts are taken from AbbVie Inc.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE -60.9% (0 of 100). Cash generation: FCF margin 28.3% (57 of 100). Net margin: 21.3% (53 of 100). Liquidity: Current 0.81× (40 of 100).
Finorify's notes from those filings, written August 31, 2026: Next-Generation Immunology Franchise Leadership. AbbVie has successfully built leading commercial franchises in Skyrizi and Rinvoq to replace Humira revenues. These therapies hold superior clinical profiles and deep market penetration across multiple chronic indications, benefiting from high switching costs and established relationships with healthcare providers and payers. Dominant Position and Brand Equity in Aesthetics and Neuroscience. Through the Botox and Allergan portfolio, AbbVie maintains an enduring competitive moat in medical aesthetics and therapeutic neurology. Botox benefits from strong global brand recognition, high practitioner loyalty, and significant cash-pay consumer exposure that reduces vulnerability to standard reimbursement and patent cliff dynamics. Global Commercial Scale and Deep R&D Infrastructure. AbbVie possesses extensive global distribution channels, mature regulatory expertise, and substantial capital resources that enable continuous label expansions for core assets, aggressive targeted acquisitions, and seamless commercial execution across major worldwide markets. Patent Expirations and Biosimilar Competition. The company faces structural revenue erosion from biosimilar and generic alternatives as core legacy blockbusters lose patent protection, which requires substantial ongoing revenue replacement from newer therapies to sustain topline growth. Government Healthcare Policy and Drug Pricing Pressures. AbbVie is heavily exposed to global healthcare pricing regulations, including Medicare drug price negotiation and rebate mandates under the U.S. Inflation Reduction Act (IRA) and single-payer price controls across international markets, which can compress gross margins. Clinical Development and Regulatory Safety Scrutiny. The business relies on successful late-stage clinical trial outcomes and regulatory clearances to refresh its pipeline. Unanticipated safety signals, regulatory delays, or class-wide warnings (such as heightened scrutiny around JAK inhibitors) can impair product adoption and reduce commercial potential.
Cash Flow
Margins
Valuation
P/E (TTM)
74.88
P/S (TTM)
7.28
EV/EBITDA
21.24
Insights
Advantage
Next-Generation Immunology Franchise Leadership
AbbVie has successfully built leading commercial franchises in Skyrizi and Rinvoq to replace Humira revenues. These therapies hold superior clinical profiles and deep market penetration across multiple chronic indications, benefiting from high switching costs and established relationships with healthcare providers and payers.
Advantage
Dominant Position and Brand Equity in Aesthetics and Neuroscience
Through the Botox and Allergan portfolio, AbbVie maintains an enduring competitive moat in medical aesthetics and therapeutic neurology. Botox benefits from strong global brand recognition, high practitioner loyalty, and significant cash-pay consumer exposure that reduces vulnerability to standard reimbursement and patent cliff dynamics.
Advantage
Global Commercial Scale and Deep R&D Infrastructure
AbbVie possesses extensive global distribution channels, mature regulatory expertise, and substantial capital resources that enable continuous label expansions for core assets, aggressive targeted acquisitions, and seamless commercial execution across major worldwide markets.
Risk
Patent Expirations and Biosimilar Competition
The company faces structural revenue erosion from biosimilar and generic alternatives as core legacy blockbusters lose patent protection, which requires substantial ongoing revenue replacement from newer therapies to sustain topline growth.
Risk
Government Healthcare Policy and Drug Pricing Pressures
AbbVie is heavily exposed to global healthcare pricing regulations, including Medicare drug price negotiation and rebate mandates under the U.S. Inflation Reduction Act (IRA) and single-payer price controls across international markets, which can compress gross margins.
Risk
Clinical Development and Regulatory Safety Scrutiny
The business relies on successful late-stage clinical trial outcomes and regulatory clearances to refresh its pipeline. Unanticipated safety signals, regulatory delays, or class-wide warnings (such as heightened scrutiny around JAK inhibitors) can impair product adoption and reduce commercial potential.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.